Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus CROLOM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus CROLOM.
ALOCRIL vs CROLOM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
2 drops in each eye four times daily; ophthalmic route.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer